Cover Image
市場調查報告書

整合&顛覆性技術時代的競爭策略

Competitive Strategies in an Era of Consolidation & Disruptive Technologies

出版商 BioInformatics, LLC 商品編碼 305955
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
整合&顛覆性技術時代的競爭策略 Competitive Strategies in an Era of Consolidation & Disruptive Technologies
出版日期: 2014年08月14日 內容資訊: 英文 100 Pages
簡介

本報告提供生命科學市場中、成長停滯時代的競爭策略分析、研究、分析的目的方式及實用策略等彙整資料,為您概述為以下內容。

主要的討論事項

  • 針對這個收購,其他的供應商應該合併嗎?
  • 為了保護核心市場,競爭企業應該從週邊市場撤退嗎?
  • 在競爭企業之間有新的聯盟嗎?
  • 小規模的生命科學企業如何帶給市場新技術?
  • 如果大企業積極地進入個體化醫療/臨床診斷,繼續著重基礎研究的供應商有職位空缺嗎?

實行預測商務策略範例:

  • 「攻擊」策略:趁新合併的企業被合併的不安、混亂分心時攻擊
  • 「磁鐵」策略:在合併休克狀態期間,為了吸引、僱用合併競爭企業的最優秀人材,構築「磁鐵策略」
  • 「威脅」策略:為了活化內部變化,利用關乎企業生存的威脅
  • 「聯盟」策略:為了刺激成長,以複數的聯盟,授權或合資經營代替合併
  • 「迅速的M&A」策略:為了獲得新技術、改善流通管道進出或擴張產品線,迅速計劃實行M&A
  • 「複合」策略:最大化成長、獲利能力,同時使用上述二個以上的策略構築複合策略

調查目的

多贊助商調查的優點

目錄
Product Code: 14-006

BioInformatics LLC, the leading research and advisory firm serving the life science tools market, will conduct an unprecedented analysis of competitive strategies in an era of flat growth, Thermo Fisher Scientific's acquisition of Life Technologies, other mergers, and disruptive technologies. This prospectus highlights the objectives and methodology of the research effort and the analysis and actionable strategies that will be delivered in the final report.

The Situation

The life science tools market has been in a near constant state of flux over the past five years as established companies have merged or been acquired, new companies are founded, and emerging technologies (such as next generation sequencing) disrupt long established markets and create new opportunities. All of this change is layered over constrained research funding in the United States and Europe and increased levels of life science spending and investment in Asia.

This market turbulence came to a head when in April 2013 Thermo Fisher Scientific (TMO) announced that it planned to acquire Life Technologies (LIFE) in a $13.6 billion transaction. On February 3, 2014, the deal closed and a $17 billion company focused on the life sciences emerged. Completion of the transaction followed the receipt of all the required regulatory approvals and included the sale of the cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for $1.07 billion. This constant state of disruption can be confusing for customers, challenging for the merging companies, and (if played appropriately) moments of opportunity for competitors.

Now what?

Life science tools companies have had a year to determine how to compete in this new market that is dominated by one very large competitor with enhanced scale, impressive channel access, and the breadth and depth of capabilities to meet customer needs in research, specialty diagnostics and applied markets. Mergers are one way for companies to respond to external market conditions that reward scale, size and cost-effectiveness. The prevailing question that this report seeks to answer is: How should life science tools companies compete in this new market environment?

  • Should other suppliers merge in response to this acquisition?
  • Will competitors retreat from peripheral markets in order to defend core markets?
  • Will there be more alliances among competitors?
  • How can smaller life science companies bring new technologies to market?
  • If major players move aggressively into personalized medicine/clinical diagnostics are there openings for suppliers who remain focused on basic research?

In light of these questions, which business strategies might be implemented?

For example:

  • "Attack" Strategy: Attack newly merged entities when they are distracted by their mergers' turmoil and confusion.
  • "Magnet" Strategy: Create a "magnet strategy" to attract and hire your merging competitors' best people while their companies are in a state of merger shock.
  • "Threat" Strategy: Use the threat to your firm's survival to jump-start internal change.
  • "Alliance" Strategy: Use multiple alliances, networks, licensing, or joint ventures - instead of mergers - to fuel growth.
  • "Fast-track M&A" Strategy: Plan and execute your firm's fast-track mergers and acquisitions to acquire new technology, increase channel access or extend product lines.
  • "Composite" Strategy: Create a composite strategy by using two or more of the above strategies simultaneously to maximize growth and profitability.

The purpose of this study is to take the pulse of the life science ecosystem to discern the effects of recent mergers, overall low growth, and disruptive technologies on suppliers and customers.

Research Objectives

  • Understand if and how competitors are adjusting their business strategies in light of recent transactions and current market conditions (e.g., pharma consolidation).
  • Ascertain how customers perceive the current life science research landscape - suppliers, channel access, research funding, research initiatives (e.g., BRAIN Initiative), science policy (e.g., translational research), and their adoption of new technology.
  • Present strategies for competing successfully in the turbulent life science market.

ADVANTAGE OF MULTI-SPONSOR RESEARCH

Mega-mergers tend to weed out marginal competitors and create opportunities for those astute enough to know what is happening around them. Multi-sponsor market research enables companies to quickly gain competitive advantage through insights that support strategic decisionmaking - at a fraction of the cost of a custom research project. Multi-sponsor research is the concept of sharing the costs and the results with a select group of market participants at a significant discount months before the results are released for general sale.

Start-Up Time

BioInformatics LLC has a multidisciplinary team of scientists, industry veterans and market research experts who will begin work upon receipt of your Sponsorship Agreement.

Expertise

BioInformatics LLC has unmatched expertise in the life science market and has delivered market studies to more than 500 unique firms.

Objectivity

BioInformatics LLC multi-sponsor research projects are unbiased and provide a fresh perspective on your strategies.

Efficiency

There is no need for pre-publication sponsors to disrupt their routine activities. BioInformatics LLC will perform all aspects of the research and deliver the final report within the required timeframe.

Cost Control

To commission a private study of similar scale and scope would cost approximately $80,000 to $100,000 USD.

Table of Contents

  • Section 1: Executive summary and overview
  • Section 2: Competitor strategies and market analysis
  • Section 3: Customer perceptions and experiences
  • Section 4: Competitive response and strategy recommendations
  • Section 5: Study methodology
  • Section 6: Additional data analysis, including verbatim comments from customers

Back to Top